文献速递骨软组织肉瘤与黑色素瘤

高危III期黑色素瘤新辅助系统治疗后淋巴结清扫的手术结局不劣于直接手术

Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery.
PubMed 文献 · Eur J Cancer · 2023-03-07

这项回顾性队列研究纳入2014年10月至2018年8月OpACIN与OpACIN-neo试验中接受新辅助抗PD1联合抗CTLA4治疗的44例高危III期黑色素瘤患者,并与同期76例直接手术者比较。结果显示两组术后并发症总发生率、术后并发症(血清肿、淋巴水肿)、手术时间及理想结局均无显著差异,作者认为新辅助免疫治疗后淋巴结清扫的手术结局与直接清扫相当。

要点

  • 新辅助组与直接手术组术后并发症总发生率分别为31.8%与36.8%,差异无统计学意义(p = 0.578)。
  • 血清肿发生率新辅助组56.8% vs 直接手术组57.9%(p = 0.908),淋巴水肿22.7% vs 13.2%(p = 0.175),均无显著差异。
  • 新辅助免疫治疗后手术时间有略延长趋势(105 vs 90 min,p = 0.077),理想结局两组相当(50% vs 49%,p = 0.889)。

核心结论

  • 作者认为,高危III期黑色素瘤患者接受新辅助系统免疫治疗后行淋巴结清扫,与直接行淋巴结清扫相比手术结局相当。

研究设计与样本

  • 回顾性队列研究,纳入2014年10月至2018年8月OpACIN(NCT02437279)和OpACIN-neo(NCT02977052)试验中接受新辅助抗PD1联合抗CTLA4治疗的高危III期黑色素瘤患者,与同期直接手术患者比较。
  • 共纳入120例患者,其中44例接受新辅助系统治疗,76例直接手术。

主要发现

  • 新辅助组与直接手术组术后并发症总发生率分别为31.8%与36.8%,差异无统计学意义(p = 0.578)。
  • 血清肿发生率新辅助组56.8% vs 直接手术组57.9%(p = 0.908),淋巴水肿发生率22.7% vs 13.2%(p = 0.175),均无显著差异。
  • 新辅助免疫治疗后手术时间有略延长趋势(105 vs 90 min,p = 0.077),差异未达统计学显著。
  • 理想结局新辅助组50% vs 直接手术组49%(p = 0.889),无差异。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Neoadjuvant systemic therapy has shown promising results in the treatment of high-risk stage III melanoma; however, the effects on surgery are currently unknown. This study aims to compare the surgical outcomes, in terms of postoperative complications, postoperative morbidity, duration of surgery and textbook outcomes, of patients with high-risk stage III melanoma who received neoadjuvant systemic therapy followed by lymph node dissection with patients who received an upfront lymph node dissection. METHODS: In this retrospective cohort study, patients with high-risk stage III melanoma treated with neoadjuvant anti-PD1 and anti-CTLA4 in the OpACIN (NCT02437279) and OpACIN-neo (NCT02977052) trial between October 2014 and August 2018 were included and compared to patients who received upfront surgery in the same time period. RESULTS: A total of 120 patients were included in this study, of whom 44 received neoadjuvant systemic therapy and 76 underwent upfront surgery. There was no significant difference in the overall rate of postoperative complications between the neoadjuvant group and the upfront surgery group (31.8% versus 36.8%, p = 0.578) and neither in rate of postoperative morbidity (seroma 56.8% versus 57.9%, p = 0.908) (lymphedema 22.7% versus 13.2%, p = 0.175). There was a non-significant difference towards a slightly longer duration of surgery after neoadjuvant immunotherapy (105 versus 90 min, p = 0.077). There were no differences in textbook outcomes (50% versus 49%, p = 0.889). CONCLUSION: This study shows that the surgical outcomes for patients who underwent a lymph node dissection after neoadjuvant systemic immunotherapy or underwent upfront lymph node dissection for high-risk stage III melanoma are comparable.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Zijlker LP, van der Burg SJC, Blank CU, et al. Surgical outcomes of lymph node dissections for stage III melanoma after neoadjuvant systemic therapy are not inferior to upfront surgery. Eur J Cancer. 2023. PMID: 36989829. doi:10.1016/j.ejca.2023.03.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。